Pathophysiology and Hemodynamic Diagnosis

This patient presented with right heart failure (RHF) after HM3 LVAD implantation, a complication affecting approximately 10% of recipients of durable LVADs that is associated with reduced survival, increased hospitalization, and diminished quality of life.¹ The pulmonary artery pulsatility index (PAPi)—defined as PA pulse pressure divided by RAP ([PASP − PADP] / RAP)—integrates RV contractile function and loading conditions into a single hemodynamic index.² In recipients of LVADs, PAPi <1.85 identifies postoperative RHF with 94% sensitivity and 81% specificity, outperforming the RAP:PCWP ratio and RV stroke work index alone.³ This patient's PAPi of 0.75 reflected severely impaired RV pulsatile function. The RAP:PCWP ratio of 0.8 further characterized the hemodynamic phenotype: A ratio exceeding 0.63 is an independent multivariate predictor of RHF in recipients of continuous-flow LVADs, distinguishing intrinsic RV dysfunction from RV dysfunction secondary to elevated left-sided filling pressures alone.¹ Together with the severely dilated hypokinetic RV, leftward septal deviation, low CI, and MvO₂ 46%, these indexes identified severe RV contractile failure with venous congestion as this patient's dominant pathophysiology. Elevated RAP simultaneously reduces forward output and imposes renal and hepatic venous hypertension, explaining the doubling of this patient's creatinine level and elevated bilirubin level. Progressive RV dilation shifts the interventricular septum leftward, impairing left ventricular (LV) geometry and reducing LVAD inflow.⁴

Dobutamine directly addresses impaired RV contractility through β₁-adrenergic stimulation. It is a racemic mixture whose isomers exert opposing vascular effects via β₂-mediated vasodilation and α₁-mediated vasoconstriction with a net hemodynamic effect that varies by clinical context. Compared with milrinone, dobutamine would be preferred in this patient because milrinone undergoes significant kidney clearance; accumulation in the setting of creatinine level 2.6 mg/dL would risk refractory hypotension that is difficult to reverse given milrinone's longer half-life.¹ Dobutamine's short half-life permits rapid titration and prompt reversal if needed. Further, cautious diuresis targets elevated RAP and venous congestion. This patient's rise in creatinine level reflected congestion-mediated kidney injury rather than intrinsic tubular damage; evidence supports continuing decongestion despite rising creatinine levels because residual congestion carries a worse prognosis than transient creatinine level elevation during diuresis.^1,5 Reducing RAP decompresses the RV, diminishes ventricular interdependence, and restores more favorable LV filling geometry, augmenting LVAD inflow and forward flow.⁶

Low LVAD flow in this patient was a consequence of RHF-mediated LV underfilling, not insufficient pump speed. Increasing pump speed accelerates LV decompression and worsens leftward septal deviation, directly impairing the septal contribution to RV systolic function.⁷ The echocardiographic finding of leftward septal shift is the imaging signature of this mechanism, not evidence of inadequate pump speed.⁸ Increasing speed treats the number rather than the disease and risks hemodynamic deterioration.

Inhaled nitric oxide is a selective pulmonary vasodilator most appropriately deployed when elevated pulmonary vascular resistance (PVR) is a primary driver of RV dysfunction. In this patient, PVR was not markedly elevated, the transpulmonary gradient was modest, and PCWP 20 mm Hg reflected a significant postcapillary component. The dominant condition was RV contractile failure with venous congestion, not pulmonary vasoconstriction. Inhaled nitric oxide without inotropic support and decongestion would leave the fundamental pathophysiology unaddressed.⁶

This patient's reduced MAP reflected a low-output state rather than vasoplegic shock. Norepinephrine increases systemic vascular resistance and, importantly, RV afterload. RV systolic function is exquisitely sensitive to afterload, with minor increases in pulmonary pressure producing disproportionately large reductions in RV stroke volume.¹ In this patient, norepinephrine's afterload-augmenting effect was potentially deleterious, and inotropic support would be the appropriate initial intervention.

Reducing pump speed can occasionally be considered when suction events or excessive LV decompression contribute to hemodynamic compromise. However, given this patient's markedly elevated RAP, low cardiac output, and cardiogenic shock physiology, the most appropriate first step would be to initiate additional inotropy rather than to reduce pump speed, which can worsen CIs.⁸ The leftward septal deviation in this patient reflected RV volume overload and ventricular interdependence, mechanistically distinct from the rightward septal deviation caused by LV collapse during suction. Reducing pump speed in a patient with CI 1.6 L/min/m² could further compromise forward output and worsen end-organ perfusion.⁷

Although not an answer choice in this patient case quiz, if the RV fails to improve after escalation of inotropic support based on CIs and echocardiographic findings, consideration of temporary RV mechanical circulatory support would offload the RV and give it additional time to recover. However, this intervention would typically be considered after a trial of inotropic support.

General Principles

Late RHF after durable LVAD implantation requires careful hemodynamic phenotyping to identify the dominant pathophysiology because interventions targeting one mechanism may worsen another.⁴ PA catheterization provides the foundation for this assessment: PAPi, RAP:PCWP ratio, CI, and MvO₂ each contribute distinct information about RV contractile reserve, biventricular filling pressure relationships, and perfusion adequacy that cannot be reliably inferred from clinical examination alone.⁹ Echocardiographic assessment of interventricular septal position complements hemodynamic data by distinguishing volume overload–mediated septal shift from suction-related LV collapse.⁸ Serial reassessment following each therapeutic intervention is essential because the pathophysiology of RHF in the LVAD-supported circulation is dynamic and the effects of individual interventions are interdependent.

References

1. Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-e622. doi:10.1161/CIR.0000000000000560
2. Geller BJ, Sinha SS, Kapur NK, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2022;146(6):e50-e68. doi:10.1161/CIR.0000000000001076
3. Morine KJ, Kiernan MS, Pham DT, Paruchuri V, Denofrio D, Kapur NK. Pulmonary artery pulsatility index is associated with right ventricular failure after left ventricular assist device surgery. J Card Fail. 2016;22(2):110-116. doi:10.1016/j.cardfail.2015.10.019
4. Rajapreyar I, Soliman O, Brailovsky Y, et al. Late right heart failure after left ventricular assist device implantation: contemporary insights and future perspectives. JACC Heart Fail. 2023;11(8 Pt 1):865-878. doi:10.1016/j.jchf.2023.04.014
5. Heidenreich PA, Fonarow GC, Breathett K, et al. 2020 ACC/AHA clinical performance and quality measures for adults with heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2020;76(21):2527-2564. doi:10.1016/j.jacc.2020.07.023
6. Tedford RJ, Leacche M, Lorts A, Drakos SG, Pagani FD, Cowger J. Durable mechanical circulatory support: JACC scientific statement. J Am Coll Cardiol. 2023;82(14):1464-1481. doi:10.1016/j.jacc.2023.07.019
7. Gopinathannair R, Cornwell WK, Dukes JW, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation. 2019;139(20):e967-e989. doi:10.1161/CIR.0000000000000673
8. Stainback RF, Estep JD, Agler DA, et al. Echocardiography in the management of patients with left ventricular assist devices: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(8):853-909. doi:10.1016/j.echo.2015.05.008
9. Rajagopalan N, Borlaug BA, Bailey AL, et al. Practical guidance for hemodynamic assessment by right heart catheterization in management of heart failure. JACC Heart Fail. 2024;12(7):1141-1156. doi:10.1016/j.jchf.2024.03.020